CRVS
Corvus Pharmaceuticals, Inc.
+0.47 (+3.84%)12.70USD472K成交股數1.1B市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-11-03下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | – | – | – | – | – | – | – | – | – | – | – |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 16.0M | 11.2M | 9.9M | 8.5M | 7.9M | 7.5M | 5.2M | 4.1M | 4.1M | 4.0M | 4.0M | 4.0M |
| 銷售管理費用 | 3.3M | 3.7M | 2.3M | 2.1M | 2.4M | 2.5M | 2.0M | 1.8M | 2.2M | 1.7M | 1.6M | 1.7M |
| 營業利益 | −19.3M+88% | −14.9M+50% | −12.2M+68% | −10.6M+78% | −10.3M+64% | −9.9M+76% | −7.3M+30% | −5.9M+6% | −6.3M | −5.7M | −5.6M | −5.6M |
| 營業利益率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 稅後淨利 | −18.0M+125% | −13.7M-190% | −12.3M-69% | −10.2M+138% | −8.0M+40% | 15.2M-329% | −40.2M+570% | −4.3M-34% | −5.7M | −6.6M | −6.0M | −6.5M |
| 淨利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 稀釋 EPS | -0.19+90% | -0.15+15% | -0.18-70% | -0.12+71% | -0.10-17% | -0.130% | -0.60+400% | -0.07-50% | -0.12 | -0.13 | -0.12 | -0.14 |
| 稀釋股數 | 92.4M | 90.0M | 79.7M | 82.8M | 77.8M | 75.2M | 66.7M | 59.7M | 49.0M | 48.0M | 49.0M | 47.5M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 18.9M | 40.1M | 4.6M | 2.9M | 14.7M | 5.0M | 4.7M | 14.8M | 7.5M | 12.6M | 20.1M | 7.7M |
| 應收帳款 | 6K | 43K | 37K | 32K | 86K | 79K | 70K | 35K | 26K | 26K | 11K | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 239M | 253M | 71.1M | 80.5M | 89.5M | 59.4M | 58.8M | 64.6M | 40.1M | 45.6M | 51.9M | 58.0M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 13.9M | 12.5M | 9.9M | 8.7M | 9.2M | 10.1M | 46.4M | 13.3M | 6.7M | 6.9M | 7.7M | 8.6M |
| 股東權益 | 225M | 241M | 61.2M | 71.8M | 80.2M | 49.3M | 12.4M | 51.2M | 33.4M | 38.7M | 44.3M | 49.5M |
| 負債比 | 5.8% | 4.9% | 13.9% | 10.8% | 10.3% | 17.0% | 78.9% | 20.7% | 16.8% | 15.1% | 14.7% | 14.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −10.4M+26% | – | – | – | −8.3M | – | – | −5.2M | – | – | – |
| 資本支出 | – | 91K | – | – | – | 36K | – | – | – | – | – | – |
| 自由現金流 | – | −10.5M+26% | – | – | – | −8.3M | – | – | – | – | – | – |
| 折舊攤銷 | 34K | 29K | 26K | 28K | 29K | 22K | 20K | 21K | 23K | 28K | 30K | 36K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | – | – | −15.3M | –% | -0.53 | −33.0M |
| FY2025 | – | – | – | –% | – | – |
| FY2025 | – | – | – | –% | – | – |
| FY2024 | – | – | −62.3M | –% | -1.02 | – |
| FY2023 | – | – | −27.0M | –% | -0.56 | −24.0M |
| FY2022 | – | – | −41.3M | –% | -0.89 | −27.3M |
| FY2021 | – | – | −43.2M | –% | -1.03 | −36.7M |
| FY2020 | – | – | −6.0M | –% | -0.20 | −34.9M |